BackCellectis Overview
Cellectis - ADR

Cellectis Target Price

Analysts' average 12-month price target for Cellectis is $4.4.

Get informed when a big investor buys or sells

+ Follow

Share Price

$1.56

Average Target Price

$4.43184.2% upside

3 analysts in the last 4 months

High: $9 | Low: $1.3

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-16BarclaysLukas Shumway$1.316.7% downsideOpen
2026-09-15Wells FargoNick Abbott$392.3% upsideOpen
2026-05-28BarclaysLukas Shumway$9476.9% upsideOpen
2025-10-20Wells FargoNick Abbott$4156.4% upsideOpen
2025-10-17BarclaysGena Wang$8412.8% upsideOpen

Cellectis (CLLS) FAQ

Cellectis posts a target price of $4.4. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $4.4 for CLLS means covering analysts, on average, see the stock 184.2% upside of $1.56 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for CLLS's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Cellectis's other metric pages and overview cover the third.

Judging Cellectis against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $4.4 here, then scan peer and history charts to see if the gap is persistent.